pembrolizumab
Pembrolizumab is a drug used to treat Melanoma, Non-small Cell Lung Cancer, Breast Cancer, and other conditions. Pembrolizumab is being actively studied in 850 studies and prior, has been studied in 133.
| Top Sponsors | Top Sites | Top Investigators |
|---|---|---|
| Merck Sharp & Dohme Corp. | Memorial Sloan Kettering Cancer Center | CCTU |
| M.D. Anderson Cancer Center | Dana Farber Cancer Institute | David Reardon, MD |
| Memorial Sloan Kettering Cancer Center | Massachusetts General Hospital | Jeeyun Lee |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Recruiting
- Gastric Cancer
- Pembrolizumab
- Seoul, Korea, Republic ofSamsung Medical Center
2021-12-23
Dec 23, 2021M
Active, not recruiting
- Thyroid
- Pembrolizumab
- Houston, TexasM D Anderson Cancer Center
2022-02-17
Feb 17, 2022I
Recruiting
- Metastatic Melanoma
- Unresectable Melanoma
- IO102-IO103
- Pembrolizumab
- Orange City, Florida
- +1 more
2022-03-11
Mar 11, 2022A
A
Not yet recruiting
- Non Hodgkin Lymphoma
- Pembrolizumab
- (no location specified)
2022-03-31
Mar 31, 2022T
Not yet recruiting
- Colorectal Cancer
- Pembrolizumab
- (no location specified)
2021-11-22
Nov 22, 2021N
Active, not recruiting
- Stage IIIA Non-Small Cell Lung Cancer
- Cisplatin
- +3 more
- Cleveland, OhioCleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
2021-07-06
Jul 6, 2021I
Not yet recruiting
- Esophagogastric Adenocarcinoma
- Pembrolizumab
- +3 more
- Heidelberg, GermanyUniversitätsklinikum Heidelberg
2022-02-24
Feb 24, 2022S
Completed
- Hepatocellular Carcinoma
- Pembrolizumab
- Seoul, Korea, Republic ofSamsung Medical Center
2022-01-25
Jan 25, 2022A
Completed
- Malignant Melanoma
- pembrolizumab
- Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
2022-03-23
Mar 23, 2022M
Active, not recruiting
- Non-small Cell Lung Cancer
- Pembrolizumab
- +4 more
- (no location specified)
2022-01-20
Jan 20, 2022J
Recruiting
- Pancreatic Cancer
- Cabozantinib
- Pembrolizumab
- Lexington, KentuckyUniversity of Kentucky Markey Cancer Center
2022-02-26
Feb 26, 2022I
Recruiting
- Lymphoma, Extranodal NK-T-Cell
- Pembrolizumab
- Involved Field Radiation Therapy
- Shanghai, ChinaShanghai Rui-Jin Hospital
2022-03-29
Mar 29, 2022M
Not yet recruiting
- Newly Diagnosed Glioblastoma
- Pembrolizumab
- (no location specified)
2022-02-22
Feb 22, 2022P
Not yet recruiting
- Metastatic Colorectal Cancer
- Encorafenib
- +2 more
- Herlev, DenmarkHerlev Hospital
2022-03-17
Mar 17, 2022M
Active, not recruiting
- Nasopharyngeal Neoplasms
- Pembrolizumab
- +3 more
- (no location specified)
2022-03-11
Mar 11, 2022B
Not yet recruiting
- Breast Cancer
- HER2-positive Breast Cancer
- Tucatinib
- +3 more
- Parkville, Victoria, AustraliaPeter MacCallum Cancer Centre
2022-03-06
Mar 6, 2022U
Active, not recruiting
- Solid Tumor
- Stereotactic body radiotherapy (SBRT)
- Pembrolizumab
- Chicago, IllinoisUniversity of Chicago
2022-03-14
Mar 14, 2022C
Active, not recruiting
- Acral Lentiginous Melanoma
- pembrolizumab
- Hong Kong, Hong KongDepartment of Clinical Oncology, Prince of Wales Hospital
2022-02-15
Feb 15, 2022U
Active, not recruiting
- Newly Diagnosed Glioblastoma
- Pembrolizumab
- Bern, Switzerland
- +2 more
2022-02-21
Feb 21, 2022U
Not yet recruiting
- Renal Cell Cancer
- Axitinib
- Pembrolizumab
- (no location specified)
2022-02-21
Feb 21, 2022Y
Terminated
- Melanoma
- Pembrolizumab
- +2 more
- Pittsburgh, PennsylvaniaUPMC Cancer Center Hillman Cancer Center
2021-12-10
Dec 10, 2021D
M
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Pembrolizumab
- Docetaxel
- (no location specified)
2021-09-07
Sep 7, 2021C
Not yet recruiting
- Pancreatic Cancer
- Pembrolizumab
- Olaparib
- (no location specified)
2021-10-21
Oct 21, 2021